New Onset Generalized Myasthenia Gravis Evolving Following SARS-CoV-2 Infection

During the SARS-CoV-2 (COVID-19) pandemic, immunogenicity of virus for various autoimmune complications has been observed. To date, a few reports have published that raise possibility new onset myasthenia gravis (MG) associated with COVID-19 infection. We report case 65-year-old male who developed his initial myasthenic presentation mild dysarthria 14 days after infection symptomatic onset. His bulbar symptoms, diplopia, and ptosis progressed considerably over next 1.5 months before he was diagnosed non-thymomatous MG. Serological tests showed high concentration anti-acetylcholine receptor anti-titin antibodies. He responded well to treatment pyridostigmine intravenous immunoglobulin. Reasonable latency from gradual evolvement symptoms makes causative association probable in this case. our knowledge, is first antibodies new-onset MG In article, we analyze previously reported cases summarize information date. discuss possible immunological mechanisms behind disease following viral features suspicion such possibility. also hint at structural homologies between spike glycoprotein titin epitopes.